Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Agenus Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with previously treated or newly diagnosed follicular center cell grade I or grade II lymphoma, small lymphocytic lymphoma, MALT lymphoma, monocytoid B-cell lymphoma, Waldenstrom's macroglobulinemia, or marginal zone lymphoma with bidimensionally measurable disease;
Part of the resected specimen must undergo routine pathologic examination to confirm the diagnosis of lymphoma. The remaining tissue must be used for the preparation of autologous HSPPC-96;
Autologous HSPPC-96 vaccine must be successfully prepared and provided by the sponsor;
A minimum of 2 grams of non-necrotic, resectable malignant lymphoma for HSPPC-96 preparation;
Bidimensionally measurable disease in at least one location other than the resected lymphoid tissue;
Life expectancy of at least 16 weeks;
Zubrod performance status of less then or equal to 2;
Adequate bone marrow function;
Adequate hepatic function;
Adequate renal function;
Signed written informed consent;
Patients of child-bearing potential must practice contraception, which is adequate in the opinion of the Principal Investigator;
Patients of child-bearing potential must have a negative serum pregnancy test prior to entry into the study and must not be lactating;
Patients must be willing to be followed at the M. D. Anderson Cancer Center during the course of treatment and follow-up;
Electrocardiogram if none performed in the prior six months;
Patients must have no chemotherapy, immunotherapy, radiotherapy, or experimental anti-cancer therapy within six weeks prior to starting autologous HSPPC-96 administration;
Patients must have fully recovered from prior anti-cancer therapy;
Tumor measurements and staging no more than 4 weeks prior to receiving the first dose of autologous HSPPC-96.
You may not be if
Patients with active or prior history of central nervous system lymphoma;
Patients with serious intercurrent medical illnesses, requiring hospitalization;
Patients with a history of primary or secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on functional immune system) or patients taking immunosuppressive drugs such as systemic corticosteroids;
Women who are pregnant or lactating;
Patients participating in another clinical trial;
Patients receiving growth factors of any kind, including G-CSF, GM-CSF, or Epogen;
Patients with bulky disease, defined as greater than 10 cm in diameter;
Patients with positive HIV antibody;
Patients with more than 4 previous treatment regimens will be excluded.
Clareo Health | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
